Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Divulging Incipient SARS-CoV-2 Delta (B.1.617.2) Variant: Possible Interference with Global Scenario

Author(s): Suman Kumar Ray and Sukhes Mukherjee*

Volume 23, Issue 1, 2023

Published on: 10 August, 2022

Article ID: e060622205636 Pages: 4

DOI: 10.2174/1871526522666220606092243

Price: $65

Abstract

SARS-CoV-2 Delta variant, also known as lineage B.1.617.2, is a variant of lineage B.1.617 of SARS-CoV-2, the virus that causes COVID-19. The B.1.617.2 variant was first discovered in India in December 2020, and by mid-April 2021, it had become the most often reported variant. On May 31, 2021, the World Health Organization (WHO) designated it as the Delta variation. Delta is 40-60% more transmissible than Alpha and nearly twice as transmissible as the original Wuhan strain of SARSCoV- 2, according to data. According to some evidence, the Delta variation may cause more severe illness in unprotected people than prior variants. A rapid increase in instances of this variation has been observed in the United Kingdom, which has been linked to travel from India and community transmission. WHO reports that the Delta version of COVID-19 has already been found in different countries throughout the world. According to the available information, the Delta variant appears to increase transmissibility, secondary attack rate, hospitalization risk, and immune escape. Due to the lack of data, the possible effects of the Delta variation on vaccination and treatment effectiveness remain unknown. However, neutralization efficiency in vaccinated people and resistance to monoclonal antibody therapy of the Delta variant have been documented in recent investigations.

Keywords: SARS-CoV-2 Delta variant, B.1.617.2, vaccine, vaccination efficacy, patent, neutralization.

Graphical Abstract

[1]
Dey S. COVID second wave in India:. Percentage of young infected in second wave same, but more serious. The Times of India. Available; https://timesofindia.indiatimes.com/india
[2]
BBC news. Delta variant: Fact-checking claims about COVID and borders. Available from: https://www.bbc.com/news/57500637
[3]
Bolze A, Cirulli ET, Luo S, et al. Rapid displacement of SARS-CoV-2 variant B.1.1.7 by B.1.617.2 and medRxiv 1.2021.06.20.21259195.
[4]
Callaway E. Delta coronavirus variant: Scientists brace for impact. Nature 2021; 595(7865): 17-8.
[http://dx.doi.org/10.1038/d41586-021-01696-3] [PMID: 34158664]
[5]
Fisman DN, Tuite AR. Progressive increase in virulence of novel SARS-CoV-2 variants in Ontario, Canada. medRxiv 2021.
[http://dx.doi.org/10.1101/2021.07.05.21260050]
[6]
Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant delta to antibody neutralization. Nature 2021; 596(7871): 276-80.
[http://dx.doi.org/10.1038/s41586-021-03777-9] [PMID: 34237773]
[7]
Plante JA, Mitchell BM, Plante KS, Debbink K, Weaver SC, Menachery VD. The variant gambit: COVID-19's next move. Cell Host Microbe 2021; 29(4): 508-15.
[http://dx.doi.org/10.1016/j.chom.2021.02.020] [PMID: 33789086]
[8]
di Giacomo S, Mercatelli D, Rakhimov A, Giorgi FM. Preliminary report on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike mutation T478K. J Med Virol 2021; 93(9): 5638-43.
[http://dx.doi.org/10.1002/jmv.27062] [PMID: 33951211]
[9]
Lubinski B, Frazier LE. V T Phan M, et al. Spike protein cleavageactivation mediated by the SARS-CoV-2 681R.bioRxiv 2021; 2021.06.30.450632.
[10]
Khateeb J, Li Y, Zhang H. Emerging SARS-CoV-2 variants of concern and potential intervention approaches. Crit Care 2021; 25(1): 244.
[http://dx.doi.org/10.1186/s13054-021-03662-x] [PMID: 34253247]
[11]
Raman R, Patel KJ, Ranjan K. COVID-19: Unmasking emerging SARS-CoV-2 Variants, vaccines and therapeutic strategies. Biomolecules 2021; 11(7): 993.
[http://dx.doi.org/10.3390/biom11070993] [PMID: 34356617]
[12]
Williams SV, Vusirikala A, Ladhani SN, et al. An outbreak caused by the SARS-CoV-2 Delta (B.1.617.2) variant in a care home after partial vaccination with a single dose of the COVID-19 vaccine Vaxzevria, London, England, April 2021. Euro Surveill 2021; 26(27): 2100626.
[http://dx.doi.org/10.2807/1560-7917.ES.2021.26.27.2100626] [PMID: 34240699]
[13]
Rizvi Z. Leading COVID-19 vaccine candidates depend on NIH technology. Public Citizen 2020. Availble; https://www.citizen.org/article/leading-COVID-19-vaccines-depend-on-nih-technology/
[14]
Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of the pfizer-biontech and oxford-astrazeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in england: Test negative case-control study. BMJ 2021; 373(1088): n1088.
[http://dx.doi.org/10.1136/bmj.n1088] [PMID: 33985964]
[15]
Olliaro P, Torreele E, Vaillant M. COVID-19 vaccine efficacy and effectiveness-the elephant (not) in the room. Lancet Microbe 2021; 2(7): e279-80.
[http://dx.doi.org/10.1016/S2666-5247(21)00069-0] [PMID: 33899038]
[16]
Lazarevic I, Pravica V, Miljanovic D, Cupic M. Immune evasion of SARS-CoV-2 emerging variants: What have we learnt so far? Viruses 2021; 13(7): 1192.
[http://dx.doi.org/10.3390/v13071192] [PMID: 34206453]
[17]
Stowe J, Andrews N, Gower C, et al. Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant. Available from: https://media.tghn.org/articles/Effectiveness_of_COVID-19_vaccines_against_hospital_admission_with_the_Delta_B._G6gnnqJ.pdf
[18]
Liu C, Zhou Q, Li Y, et al. Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci 2020; 6(3): 315-31.
[http://dx.doi.org/10.1021/acscentsci.0c00272] [PMID: 32226821]
[19]
Rosenfeld R, Noy-Porat T, Mechaly A, et al. Post-exposure protection of SARS-CoV-2 lethal infected K18-hACE2 transgenic mice by neutralizing human monoclonal antibody. Nat Commun 2021; 12(1): 944.
[http://dx.doi.org/10.1038/s41467-021-21239-8] [PMID: 33574228]
[20]
Gaviria M, Kilic B. A network analysis of COVID-19 mRNA vaccine patents. Nat Biotechnol 2021; 39(5): 546-8.
[http://dx.doi.org/10.1038/s41587-021-00912-9] [PMID: 33981074]

Rights & Permissions Print Cite
Article Metrics
14
2
© 2024 Bentham Science Publishers | Privacy Policy